BI

(redirected from Boehringer Ingelheim)
Also found in: Wikipedia.
AcronymDefinition
BIBisexual
BIBurundi (ISO country code)
BIBusiness Intelligence
BIBank Indonesia
BIBrain Injury
BIBohemia Interactive (game development company)
BIBlock Island (Rhode Island)
BIBackground Information
BIBlack Ice (Star Wars novel)
BIBielefeld (Germany)
BIBoehringer Ingelheim (Germany)
BIBacterial Infection
BIBismuth
BIBritish India
BIBidirectional
BIBuddy Icon
BIBusiness Income
BIBusiness Improvement
BIBrookings Institution
BIBusiness Interruption (insurance)
BIBodily Injury
BIBlack Iron
BIBiological Indicator
BIBusiness Integration
BIBurn-In
BIBainbridge Island (Washington state)
BIBackground Investigation
BIBad Influence (band)
BIBurning Issues
BIBanca d'Italia (Italian central bank)
BIBusiness Instruction
BIBrain Informatics
BIBilling Instructions
BIBehavioral Interventions
BIBeyond Imagination
BIBarthel Index
BIRoyal Brunei Airlines (IATA airline code)
BIBus Interconnect
BIBritish Israelism
BIBinary Input
BIBubble Interface
BIBumrungrad International (Thailand)
BIBreidbart Index (USENET spam metric)
BIBibliographisches Institut (German book publisher)
BIBody Inflation (artificial physical transformation)
BIBiella, Piemonte (Italian province)
BIBribie Island (Australia)
BIBriefing to Industry
BIBirth Index
BIBavarian Inn (Lake Ronkonkoma)
BIBloody Idiot
BIBaccalauréat International (French: International Baccalaureate)
BIBook Inventory
BIBeer Institute
BIBiographical Inventory (US Navy)
BIBiot Number (heat transfer)
BIBroadcast Intelligence
BIBattlefield Information
BIBefore Internet
BIBraniff International (defunct US airline)
BIBackplane Interconnect
BIBuffer Index
BIBusiness Impact Test
BIBibliotheca Islamica (Islamic Library - German Oriental Society)
BIbattle injury (US DoD)
BIBasis of Issue
BIBlanking Input
BI(Run) Batted In (Baseball)
BIBattlespace Infosphere
BIBackward Indicator
BIBase-In Prism (ophthalmology)
BIBehavior Inhibition (psychology)
BIBranch Immaterial
BIBattlefield Illumination
BIBebco Industries (La Marque, TX)
BIBatch Interactive (IBM)
BIBattlefield Interdiction
BIBasketball Ireland
BIBeni Immobiliari (Italian)
BIBrand Institute, Inc (Miami, FL)
BIBranch Insertion
BIBell Intrigna
BIBiotehnologii Industriale (Romania)
BIBayer Industrieprodukte (Cologne, Germany)
BIBuild Increment
BIBannockburn Institute
BIBilhete de Identificação
BIBedriftsokonomisk Institutt (Norwegian: Business Institute)
BIBrigade Internationaliste
BISignaling Identification Assigned By Exchange B
BIBrinch Import
References in periodicals archive ?
Ingelheim, Germany- and Boston, Massachusetts-based Boehringer Ingelheim has increased funding for its corporate venture fund, known as the Boehringer Ingelheim Venture Fund (BIVF), from EUR 100 to 250 m, the company said.
M2 EQUITYBITES-December 21, 2017-Evox Therapeutics signs research collaboration with Boehringer Ingelheim
Boehringer Ingelheim, one of the leading pharmaceutical companies worldwide, is set to open a shared services center in the Philippines as part of its global expansion program.
In the Philippines, Boehringer Ingelheim is likewise an industry leader, recognized as one of the largest multinational pharmaceutical companies in the country.
Joachim Hasenmaier, Member of the Board of Managing Directors of Boehringer Ingelheim, in Beijing on 17 October 2017.
Boehringer Ingelheim recently inaugurated its commercial production site for biopharmaceuticals in Zhang Jiang Hi-tech Park of Shanghai, China.
03 January 2017 - French drugmaker Sanofi and German drugmaker Boehringer Ingelheim have closed the exchange of Sanofi's animal health business and Boehringer Ingelheim's consumer healthcare business, the companies said.
HEALTHY MOVE: The partnership between Boehringer Ingelheim, Cigalah and Tabuk is aimed at optimization of the packaging process and providing medicines as finished goods.
Boehringer Ingelheim, one of the world's leading pharmaceutical companies, has entered into a tripartite agreement for local production in Saudi Arabia with Cigalah and Tabouk.
Boehringer Ingelheim Pharmaceuticals says it has made more than $350 million worth of capital investments throughout its operations across the United States this year to bolster its drug discovery, development and manufacturing capabilities.
Boehringer Ingelheim Consumer Health Care says its partnership with the Colon Cancer Alliance has proved so successful that it will be extended through 2012.
Boehringer Ingelheim has initiated a Phase III clinical study of BIBW 2992 as a first-line treatment for NSCLC (non-small cell lung cancer) patients with EGFR (epidermal growth factor receptor) mutations.